TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02680158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Intranasal
Description: Oculeve device, intranasal (test) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham
Description: Sham device (control), intranasal application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oculeve Extranasal
Description: Oculeve device, extranasal (control) application for approximately 3 minutes.
Study: NCT02112396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Reinforcement and Family Training
Description: The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community Reinforcement and Family Training
Description: The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
Study: NCT03939858

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Tests have been selected to represent a range of cognitive functions affected by cancer and radiotherapy including basic attention, recent memory, executive functions (spanning verbal fluency, cognitive set-shifting, and abstract reasoning), and visual perceptual/spatial skills.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: 16 ml of blood will be collected before 10 a.m. and after the participant has fasted for 8 hours. White blood cells and platelets will be used for respirometric analysis. Plasma will be additionally processed and saved in 500uL aliquots(x2) and the remainder in 1mL aliquots at -80°C.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bioenergetic Profiling
Description: Peripheral blood mononuclear cells (PBMCs) and platelets will be separated from the blood. Primary respirometric parameters will be measured with high-throughput respirometry using the Agilent Seahorse 24XFe. Additional parameters will be collected with high-resolution respirometry using the OROBOROS Oxygraph-2k. Both methods will report a variety of mitochondrial parameters resulting in 48 measures per participant, creating robust profiles of bioenergetic health. Additional analysis will include western blots to enumerate protein density for the five major mitochondrial complexes, mtDNA copy number analysis, and citrate synthase activity as these assays provide different but complementary data to respirometry for a more dynamic picture of mitochondrial metabolism.
Study: NCT01247467

Intervention type: OTHER
Intervention: Breast Tumor Blocks
Study: NCT00984100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NOTES Transvaginal Cholecystectomy
Description: An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
Study: NCT02176031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Study: NCT03301272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A Injection
Description: Reconstituted 10 units/0.1 mL. Administered intramuscular once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A Injection
Description: Reconstituted 10 units/0.1 mL. Administered intramuscular once

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Study: NCT03807726

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation breastfeeding education
Description: The integrated interventions are consisted of 1) four sessions of simulation breastfeeding education to build up the participants' performance accomplishment and vicarious learning including breastfeeding knowledge, skill, and self-efficacy; 2) two sessions of breastfeeding mindfulness training to equip women and their partners with stress reduction skills for their emotional arousal during breastfeeding; 3) a series of postpartum professional support to offer verbal persuasion in enhancing their breastfeeding skills and levels of self-efficacy.
Study: NCT03054662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implement non haemostatic care of haemophilia
Description: Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
Study: NCT01395329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebivolol
Description: 5 mg tablet to be taken by mouth once per day for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol
Description: 100 mg tablet to be taken by mouth once per day for 12 weeks
Study: NCT01625494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine (150/5mg)
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine (150/10mg)
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine (300/5mg)
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan/Amlodipine (300/10mg)
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT00749840

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire taking 60-90 minutes.
Study: NCT00409747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Study: NCT04619498

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PediAppRREST
Description: PediAppRREST is a new audiovisual interactive app for tablets developed to support the management of pediatric cardiac arrest. It sequentially displays directions on recommended management interventions. It was specifically designed to guide the team leader to perform resuscitation interventions in the sequence/timing and modality reported by the American Heart Association Pediatric Advanced Life Support (AHA-PALS) guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AHA-PALS pocket reference card
Description: It is a 10 cm x 16.5 cm, full-color, 2-sided, 6-panel card that shows the American Heart Association Pediatric Advanced Life Support (AHA-PALS) treatment algorithms. By providing a quick reference tool, it serves as a cognitive aid for healthcare providers who either direct or participate in the management of pediatric respiratory and/or cardiovascular emergencies, including cardiac arrest.
Study: NCT03858556

Intervention type: PROCEDURE
Intervention: Chuna manipulation
Description: Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
Study: NCT04713501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PARTS Program
Description: The PARTS Program is a 16-week group intervention model, with 8 individual clinical sessions on a biweekly basis, developed to resolve and alleviate trauma and stress for individuals diagnosed with PTSD.
Study: NCT03858556

Intervention type: DRUG
Intervention: Herbal medicine
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).

Intervention type: PROCEDURE
Intervention: Bee venom pharmacopuncture
Description: Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Pharmacopuncture
Description: Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Intervention type: PROCEDURE
Intervention: Acupuncture
Description: Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Electroacupuncture
Description: Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

Intervention type: PROCEDURE
Intervention: Cupping
Description: Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
Study: NCT01141491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent ganglioside vaccine
Description: Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
Study: NCT03858556

Intervention type: OTHER
Intervention: Other intervention(s)
Description: Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
Study: NCT03851809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Wendan decoction combination in acute brain injury
Description: In the intervention group, traditional Chinese medicine was given between 14 days of onset and TCM was used 1 month at least in intervention group.
Study: NCT02365402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
Study: NCT01277679

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI of lungs to measure lung water content before and after passive leg raising (PLR)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: MRI
Description: MRI of lungs to measure lung water content before and after passive leg raising (PLR)
Study: NCT04791917

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Biceps Flexion
Description: Muscle lengthening biceps exercise
Study: NCT03301272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
Study: NCT00121251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study: NCT03567980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crisaborole
Description: Application of topical crisaborole 2% ointment on the face for 4 weeks to evaluate the anti-inflammatory action of this agent and its utility in the treatment of facial seborrheic dermatitis.
Study: NCT00261950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensipar (Cinacalcet HCl)
Description: All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
Study: NCT01141491

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: OPT-821
Description: Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
Study: NCT02777827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol 0.156 μg
Description: Dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Description: Dry powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol 0.05 μg
Description: Pressurised metered-dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol 0.156 μg
Description: Pressurised metered-dose inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abediterol 2.5 μg
Description: Pressurised metered-dose inhaler

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pressurised metered-dose inhaler and dry powder for inhalation.
Study: NCT03420885

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ba Duan Jin
Description: Ba Duan Jin, a traditional Chinese health-preserving technique, combines the traditional Chinese medicine and traditional Chinese philosophy and embrace the body, breath and spirit. Ba Duan Jin consists of eight main movements. According to traditional theory, every movement has unique effect to different Zang-fu organs.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education
Description: Health education includes work, rest, diet and other basic programs according to the different conditions of participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Health education includes work, rest, diet and other basic programs according to the different conditions of participants.
Study: NCT02211456

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol
Description: Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
Study: NCT00924443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine
Study: NCT00803062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan Hydrochloride
Description: Given IV
Study: NCT02836431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1mcg/kg Intranasal
Description: DEX 1 mcg/kg Intranasal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2mcg/kg Intranasal
Description: DEX 2 mcg/kg Intranasal
Study: NCT01395329

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: gelatin capsule to be taken by mouth once per day for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
Description: The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
Description: The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Forearm Blood Flow (FBF) response to BQ-123 (100 mol/min)
Description: The forearm blood flow response to the endothelin (ET) -1 A receptor blocker BQ-123 (100 nmol/min) for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FBF response to BQ-123 (100 nmol/min)+BQ-788(50 nmol/min)
Description: The FBF response to the nonselective endothelin (ET) -1 receptor blockade BQ-123 (100 nmol/min) + BQ-788 (50 nmol/min)for 60 minutes at baseline and at 12 weeks.
Study: NCT00121251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO